India continues to progress in AIDS vaccine development efforts

August 18, 2008

A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced. The results of the trial of an MVA-based AIDS vaccine candidate (TBC-M4), which was conducted in Chennai, indicated that the vaccine candidate had acceptable levels of safety and was well tolerated.

The proportion of volunteers whose immune systems responded to the vaccine candidate suggests the candidate holds promise. The trial was done using two doses of the candidate vaccine. After three injections, 82 percent of the volunteers who received a low dose and 100 percent of those who received a high dose registered immune responses to the vaccine. The 100 percent response rate is greater than that seen with the majority of AIDS vaccine candidates tested in humans to date. However the strength and diversity of these immune responses were modest. It may be possible to boost the immune response, if this vaccine is used in combination with other candidate AIDS vaccines.

"We are pleased to see that the MVA-based candidate tested in Chennai was safe and showed promising initial immune responses. We do not know whether these observed responses will ultimately translate into an effective vaccine that will help protect individuals from HIV infection, but hope to learn more through further testing," said Dr. S K Bhattacharya, Additional Director General of the Indian Council of Medical Research. "India is playing a significant role in global AIDS vaccine discovery efforts given our strong medical and scientific capabilities. There is a need for continued efforts for the creation of novel, reliable mechanisms for long-term research on AIDS vaccines and other new prevention technologies."

The Phase I clinical trial was initiated in January 2006 at the Tuberculosis Research Center (TRC), an Indian Council of Medical Research (ICMR) institute in Chennai, and was completed in February 2008. This trial was conducted under the aegis of a Memorandum of Understanding (MoU) between the Government of India-through the Indian Council of Medical Research (ICMR) and the National AIDS Control Organization (NACO)-and the not-for-profit International AIDS Vaccine Initiative (IAVI). YRG CARE, based in Chennai, collaborated with TRC to mobilize the community around the Phase I trial.

Dr. Narayanan, former Director of the Tuberculosis Research Center, added, "Consistent innovation in science despite setbacks has ensured the development of many effective prevention technologies. The successful conduct of the trial in Chennai re-affirms the need for continued vaccine development initiatives, where learnings from every effort will contribute to global advancement of the AIDS vaccine field."

About the Phase I MVA-based (TBC-M4) AIDS vaccine trial

The trial was a double blind, dose-escalation, randomized, placebo-controlled trial, which was initiated after receiving all necessary regulatory and ethical clearances. The objectives of such a Phase I trial are to evaluate the safety of the vaccine candidate and to gather preliminary results of immune responses induced by the candidate. The total duration of the trial was approximately 24 months. The volunteers recruited for this trial were 32 healthy, HIV-uninfected men and women between 18 and 50 years of age, from all socio-economic strata. Three intra-muscular injections of TBC-M4 or placebo were administered to the volunteers.

Moving forward

The results of the Phase I vaccine trial of TBC-M4 suggest that further research is warranted. Currently, two additional Phase I trials testing the MVA-based candidate in a prime-boost regime are planned and under review by the relevant authorities in India and approved in the UK. The trials are designed to use different modes of administration of the priming vaccine, different dosages and different vaccine regimens. It is hoped that the prime-boost regimen will help to strengthen the modest immune responses observed in the Phase I trial of the MVA-based candidate alone. Collectively, the results will help determine whether and how to move forward with additional testing of this MVA-based AIDS vaccine candidate.

Simultaneously, IAVI has undertaken work to modify the MVA-based vaccine candidate so that it is ready for large-scale manufacturing should the trial results suggest further testing is warranted.

International AIDS Vaccine Initiative

---

---

	Big Shot: Passion, Politics, and the Struggle for an AIDS Vaccine by Patricia Thomas (Author) A veteran journalist dramatizes the controversial search for an AIDS vaccine-the players, the politics, the money-in a vivid, suspenseful story that reveals how science is done, and not done, in America today. . When the human immunodeficiency virus was identified in 1984, the competition to create an AIDS vaccine was fierce. Now Patricia Thomas brings the contenders to life in a fast-paced, dramatic narrative: Two biologists rescue precious virus cultures from destruction by a military biohazard team. Other researchers drive hundreds of miles during a heat wave to work in a safe containment lab. And a heroic figure from Randy Shilts's And The Band Played On just might win the vaccine marathon. Thomas shows how the scientists' youthful optimism is honed into gritty determination as they...
	AIDS Vaccine Research by WonG-Staal/Gall (Author) This reference describes the latest advances in the development and design of an HIV preventive vaccine-detailing the pathogenesis and genetic variability of HIV infection for the construction of molecular and therapeutic strategies to reduce the progression and transmission of AIDS. With contributions by universally recognized authorities in the field, AIDS Vaccine Research discusses § major obstacles in the identification of a preventive vaccine § the role of innate immunity in management of HIV infection § the impact of highly active antiretroviral therapy (HAART) on AIDS research § the creation of an effective mucosal DNA vaccine § the effect of the AIDS epidemic on developing countries Offering nearly 2000 contemporary references to facilitate further study, AIDS Vaccine...
	Shots in the Dark: The Wayward Search for an AIDS Vaccine by Jon Cohen (Author) "[A]n important book not only for the now but for the future of this epidemic and those to come."—Dr. Robert GalloWhen scientists proved in 1984 that HIV causes AIDS, a vaccine race spun into action. But the sprint to develop an AIDS vaccine now more closely resembles a crawl. Jon Cohen elucidates the forces that have hindered the search: unforeseen scientific obstacles, clashing personalities, the uncertain marketplace, haphazard political organization, and serious ethical dilemmas. Beyond a powerful critique, Cohen also offers specific recommendations for accelerating the effort. 6 pages of b/w photographs.
	HIV And Molecular Immunity: Prospects for the AIDS Vaccine by Omar Bagasra (Author) How old is the AIDS virus (HIV-1) and where did it come from? Is it the result of a recombinant event in simian immunodeficiency viruses (SIVs)? Why do SIVs naturally occur in a variety of nonhuman African primates without inducing AIDS in their natural hosts? HIV-1 has devastated human society, although chimpanzees carry an SIV that is genetically almost identical to HIV-1 but causes no known illness in these great apes. How are Chimpanzees immune to HIV-1? Can humans acquire this immunity? Why do most newborns infected with HIV-1 in utero or during birth become long-term non-progressors while 20% rapidly develop AIDS and die in less than a year? Why are some adults asymptomatic for over 10 years after infection? Dr. Omar Bagasra, an eminent molecular biologist, immunologist, and...
	AIDS Vaccine Development: Challenges and Opportunities by Wayne Koff (Editor), Patricia Kahn (Editor), Ian D. Gust (Editor) The HIV/AIDS pandemic is the most devastating global public health crisis since the great plagues of the Middle Ages, with more than 14,000 new HIV infections and 8,000 deaths due to AIDS every day. Although successful vaccines have been developed for most common childhood diseases, the development of a vaccine against the AIDS virus is a much greater challenge. More than 20 years after the discovery of the virus, the goal of a licensed and globally accessible vaccine is still several years away. AIDS Vaccine Development reviews the scientific challenges that have impeded the search for an effective AIDS vaccine and discusses current novel research that is accelerating progress. In a series of mini-reviews by the world's leading experts in AIDS vaccine research, the book provides...
	Immunology: From Pasteur to the Search for an AIDS Vaccine (Venture Books) by Martin J. Gutnik (Author) A history of immunology from the discovery of microorganisms with the invention of the microscope to the development of vaccines for treating diseases.
	Vaccines 91: Modern Approaches to New Vaccines Including Prevention of AIDS by Robert M. Chanock (Author), H. Ginsberg (Author), F. Brown (Author), R. Lerner (Editor)
	Adoption of Health Technologies in India: Implications for the AIDS Vaccine (Studies in Economic and Social Development) by Indrani Gupta (Author), Mayur Trivedi (Author), Subodh Kandamuthan (Author) The first of its kind, this book examines the adoption of four health technologies in India-Hepatitis B, No Scalpel Vasectomy, Voluntary Counseling and Testing, and Antiretroviral Treatment. Using a set of parameters, the authors not only bring to light the various dimensions, strengths, and weaknesses of adoption of health technologies in India, but also how and where more attention needs to be paid with regard to the adoption of the AIDS vaccine.
	Expanding Access to Investigational Therapies for HIV Infection and AIDS by Roundtable for the Development of Drugs and Vaccines Against AIDS (Author), Institute of Medicine (Author) The call for a "parallel track" for AIDS drug development-a proposal that would allow the early distribution of AIDS drugs to large numbers of patients in parallel with the conventional clinical trials that assess the drugs' safety and efficacy-has sparked controversy within the scientific community. Questions have arisen about the risks to patients of such a plan, about its potential effect on the successful completion of standard controlled trials, and about whether the parallel track will generate useful data. Larger questions have also been raised about whether the parallel track heralds fundamental changes in the philosophy underlying drug regulation in the United States, about the costs and financing of investigational therapies and associated medical costs, and about the role of...
	Vaccines 97 by Fred Brown (Author), Fred Brown (Editor), Dennis Burton (Editor), Peter Doherty (Editor), John Mekalanos (Editor), Erling Norrby (Editor) USDA, Plum Island Animal Disease Center. Proceedings from the meeting held September 9-13, 1996. Presentation of research on new approaches to infectious disease control. For the investigator. Softcover.